Processa Pharmaceuticals (NASDAQ: PCSA) grants director 33,500 RSUs and options
Rhea-AI Filing Summary
Processa Pharmaceuticals, Inc. director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. Each RSU represents a contingent right to one share of common stock and vested upon grant, with distribution deferred until the earlier of termination, six months after grant, a change of control, or death. Following this grant, he holds 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.96, and common stock totaling 353 shares directly plus additional indirect holdings, all reflecting a 1-for-25 reverse stock split effected on December 17, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Yorke Justin W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F3 | 33,500 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F2, F3 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 38,749 shares (Direct);
Stock Options (Right to Buy) — 12,000 shares (Direct);
Common Stock — 353 shares (Direct);
Common Stock — 1,250 shares (Indirect, By Richland Fund, LLC);
Common Stock — 496 shares (Indirect, By Directed Trust Company FBO Justin Yorke IRA)
Footnotes (3)
- F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
- F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Key Figures
RSUs granted: 33,500 RSUs
RSU holdings after grant: 38,749 RSUs
Option exercise price: $4.96 per share
+5 more
8 metrics
RSUs granted
33,500 RSUs
Grant of Restricted Stock Units to director on July 26, 2026
RSU holdings after grant
38,749 RSUs
Total Restricted Stock Units held by Justin W. Yorke following the grant
Option exercise price
$4.96 per share
Exercise price of stock options covering 12,000 shares of common stock
Stock options underlying shares
12,000 shares
Common shares underlying Stock Options (Right to Buy), held directly
Direct common shares
353 shares
Directly owned Processa Pharmaceuticals common stock
Indirect shares via Richland Fund, LLC
1,250 shares
Common stock held indirectly through Richland Fund, LLC
Indirect shares via IRA trust
496 shares
Common stock held indirectly via Directed Trust Company FBO Justin Yorke IRA
Reverse stock split ratio
1-for-25
Reverse stock split effected on December 17, 2025, reflected in reported holdings
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), 1-for-25 reverse stock split, change of control
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) vest one-third on the first anniversary date"
1-for-25 reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
change of control financial
"distributed until the earlier of termination; six month anniversary; change of control; or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Justin W. Yorke receive from Processa Pharmaceuticals (PCSA) in this Form 4?
Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Processa Pharmaceuticals common stock, and the RSUs vested immediately on the July 26, 2026 grant date.
When will the 33,500 RSUs granted to Justin W. Yorke by PCSA be distributed?
The 33,500 RSUs will be distributed at the earlier of termination, six months after the grant date, a change of control, or death. Although the RSUs vested upon grant, actual share delivery is deferred until one of these specified triggering events occurs.
What are Justin W. Yorke’s RSU and option holdings in PCSA after the reported transactions?
After the reported grant, Justin W. Yorke holds 38,749 RSUs and stock options covering 12,000 shares of Processa common stock at an exercise price of $4.96 per share. These positions reflect the company’s previously effected 1-for-25 reverse stock split.
Were Justin W. Yorke’s PCSA transactions reported as made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the transactions were not affirmed as made under a Rule 10b5-1 trading plan. The document-level checkbox for transactions pursuant to a Rule 10b5-1 plan is not marked as true for this filing.
How do the stock options reported for Justin W. Yorke in PCSA vest over time?
The stock options for 12,000 shares at $4.96 vest one-third on the first anniversary of the grant date, with the remaining two-thirds vesting ratably over the following two years, according to the vesting footnote in the filing.